Zydus Lifesciences’ wholly-owned subsidiary -- Sentynl Therapeutics Inc. (Sentynl), a U.S.-based biopharmaceutical company, has entered into an agreement with PRG S&T, a Korean company specializing in the development of medicine for rare genetic diseases, to license its investigational molecule Progerinin (SLC-D011) for Hutchinson-Gilford Progeria Syndrome (HGPS or progeria).

The agreement will allow Sentynl to begin working with PRG S&T immediately to advance the clinical development of Progerinin for HGPS, which has been designated as an orphan drug by the United States Food and Drug Administration (FDA). Under the conditions that certain steps are met, Sentynl will acquire full rights to the molecule for HGPS upon closing, making Progerinin the company’s second therapy intended for the treatment of HGPS. The program is currently finalizing a Phase 2A clinical trial and data are expected before the end of 1H 2026.

Zydus Lifesciences (formerly known as Cadila Healthcare), a company limited by shares, incorporated and domiciled in India, operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.